Edarbi high blood pressure medication gets FDA approval
|
(Best Syndication News) - The US Food and Drug Administration (FDA) announced the approval of Edarbi tablets or azilsartan medoxomil prescription drug to adults to get treatment for high blood pressure which is also called hypertension. Takeda Pharmaceutical North America of Deerfield, Illionois is the pharmaceutical company that makes the Edarbi medication.
Edarbi clinical studies showed that it could be more effective in lowering 24-hour blood pressure compared to Diovan (valsartan) and Benicar (olmesartan). Dosages will be in either 40 or 80 milligram portions. The FDA said that the recommended dose will be set at 80 milligrams taken once daily. The 40 milligram dose will be for patients that are already taking high-dose diuretics.
The way the Edarbi works to lower blood pressure is by blocking the action of the angiotensin II, a vasopressor hormone. It is considered an angiotensin II receptor blocker (ARB).
There is a box warning for pregnant women for Edarbi. The medication can cause injury or death to the fetus during the second and third trimester. If a women becomes pregnant they should discontinue taking and consult with their doctor about other options.
BY: N Wilson
 |
|
|
|
||
|
|